Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors

Perez, B.; Aljumaily, R.; Marron, T.U.; Shafique, M.R.; Burris, H.; Iams, W.T.; Chmura, S.J.; Luke, J.J.; Edenfield, W.; Sohal, D.; Liao, X.; Boesler, C.; Machl, A.; Seebeck, J.; Becker, A.; Guenther, B.; Rodriguez-Gutierrez, A.; Antonia, S.J.

doi:10.1016/j.esmoop.2023.102217

Cited by 3 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subset of patients with PD-L1 < 1%, the median OS was 1.6 months (95% CI 1.0–19.6), while for the subset of patients with PD-L1 > 1%, the data were not reached (32364844). Clinicians have started investigating the combination of immunotherapy and radiotherapy ( 20 , 21 ). In head and neck cancer, a synergistic effect has been found as both irradiated sites and metastatic lesions achieved responses ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

Wang,

Lin,

Kuang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundFor patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we collected the prospective data reported since 2010 to analyze the emerging chemotherapy-based treatments in ATC comprehensively.MethodsFor this updated analysis, we searched PubMed (MEDLINE), Web of Science, Embase, and Cochrane CENTRAL databases from 1 January 2010 to 7 February 2024 for prospective clinical studies that contained chemotherapy-based treatments. This analysis was done to pool overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), disease control rates (DCRs), and grade 3 or worse treatment-related adverse events (TRAEs).ResultsSix prospective clinical trials with 232 patients were included. Chemotherapy was commonly combined with targeted therapy or radiotherapy. The pooled median OS was 6.0 months (95% CI 4.1–9.7), and the median PFS was 3.2 months (95% CI 1.9–6.0) in patients with ATC who received chemotherapy-based strategies. The integrated ORR and DCR were 21% (95% CI 15%–27%) and 64% (95% CI 55%–72%), respectively. Regarding the grade 3 or worse TRAE, the pooled incidence was 68% (95% CI 47%–86%).ConclusionAlthough the emerging chemotherapy-based treatments showed antitumor activity in patients with ATC, these strategies failed to prolong the survival time substantially. More practical, safe, and novel therapeutic regimens for patients with ATC warrant further investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

Wang,

Lin,

Kuang

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…In the subset of patients with PD-L1 < 1%, the median OS was 1.6 months (95% CI 1.0-19.6), while for the subset of patients with PD-L1 > 1%, the data were not reached (32364844). Clinicians have started investigating the combination of immunotherapy and radiotherapy (20,21). In head and neck cancer, a synergistic effect has been found as both irradiated sites and metastatic lesions achieved responses (21).…”

Section: Discussionmentioning

confidence: 99%